Compare ESQ & KALV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ESQ | KALV |
|---|---|---|
| Founded | 2006 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Commercial Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 941.0M | 1.0B |
| IPO Year | 2017 | 2014 |
| Metric | ESQ | KALV |
|---|---|---|
| Price | $111.11 | $26.79 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 5 |
| Target Price | ★ $120.33 | $32.60 |
| AVG Volume (30 Days) | 83.8K | ★ 5.4M |
| Earning Date | 04-23-2026 | 07-09-2026 |
| Dividend Yield | ★ 0.76% | N/A |
| EPS Growth | ★ 14.20 | N/A |
| EPS | ★ 1.40 | N/A |
| Revenue | N/A | ★ $50,000,000.00 |
| Revenue This Year | $35.15 | $185.42 |
| Revenue Next Year | $39.09 | $59.23 |
| P/E Ratio | $79.64 | ★ N/A |
| Revenue Growth | N/A | ★ 495.66 |
| 52 Week Low | $87.54 | $9.83 |
| 52 Week High | $119.86 | $26.85 |
| Indicator | ESQ | KALV |
|---|---|---|
| Relative Strength Index (RSI) | 57.72 | 74.68 |
| Support Level | $103.31 | $14.25 |
| Resistance Level | $116.59 | $26.85 |
| Average True Range (ATR) | 2.64 | 0.07 |
| MACD | 0.72 | -0.22 |
| Stochastic Oscillator | 84.05 | 71.05 |
Esquire Financial Holdings Inc is a financial holding company operating as a full service commercial bank. It serves the financial needs of the litigation industry and small businesses nationally, as well as commercial and retail customers in the New York metropolitan area. The bank offers tailored financial and payment processing solutions to the litigation community and their clients as well as dynamic and flexible payment processing solutions to small business owners. It operates in one operating segment, that of community banking.
KalVista Pharmaceuticals Inc is a pharmaceutical company developing and delivering oral therapies for individuals affected by rare diseases with unmet needs. The company applies its knowledge in the kallikrein-kinin system (KKS) and oral drug discovery to develop small-molecule protease inhibitor medicines to address the needs of patients with diseases driven by plasma kallikrein and Factor XIIa. Its FDA-approved product EKTERLY (sebetralstat) is a novel, orally delivered, small-molecule plasma kallikrein inhibitor for the treatment of acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged twelve years and older.